Bruck Kifle

Array ( [id] => 9756269 [patent_doc_number] => 20140286970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/351168 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756269 [patent_doc_number] => 20140286970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/351168 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756269 [patent_doc_number] => 20140286970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/351168 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670484 [patent_doc_number] => 20140234346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'PYRROLOBENZODIAZEPINES' [patent_app_type] => utility [patent_app_number] => 14/351175 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22611 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756269 [patent_doc_number] => 20140286970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/351168 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9719645 [patent_doc_number] => 20140255344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'Antiviral Compounds' [patent_app_type] => utility [patent_app_number] => 14/351029 [patent_app_country] => US [patent_app_date] => 2012-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21018 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10870348 [patent_doc_number] => 08895545 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-25 [patent_title] => 'Acrylamide derivatives as Fab I inhibitors' [patent_app_type] => utility [patent_app_number] => 13/644351 [patent_app_country] => US [patent_app_date] => 2012-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 45109 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13644351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8638172 [patent_doc_number] => 20130029975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'CGRP ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/633322 [patent_app_country] => US [patent_app_date] => 2012-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53210 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13633322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10057263 [patent_doc_number] => 09096609 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-04 [patent_title] => 'Macrocyclic LRRK2 kinase inhibitors' [patent_app_type] => utility [patent_app_number] => 14/348138 [patent_app_country] => US [patent_app_date] => 2012-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 59612 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14348138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10050763 [patent_doc_number] => 09090630 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-28 [patent_title] => 'Macrocyclic FLT3 kinase inhibitors' [patent_app_type] => utility [patent_app_number] => 14/347750 [patent_app_country] => US [patent_app_date] => 2012-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38060 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767026 [patent_doc_number] => 20130095063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'Compounds for the Treatment of Hepatitis C' [patent_app_type] => utility [patent_app_number] => 13/628529 [patent_app_country] => US [patent_app_date] => 2012-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8890 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13628529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9671768 [patent_doc_number] => 20140235629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/347628 [patent_app_country] => US [patent_app_date] => 2012-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 199606 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10115637 [patent_doc_number] => 09150508 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-06 [patent_title] => 'Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor' [patent_app_type] => utility [patent_app_number] => 14/347018 [patent_app_country] => US [patent_app_date] => 2012-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33756 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8732645 [patent_doc_number] => 20130078214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-28 [patent_title] => 'Compounds for the Treatment of Hepatitis C' [patent_app_type] => utility [patent_app_number] => 13/625186 [patent_app_country] => US [patent_app_date] => 2012-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12070 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13625186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10912871 [patent_doc_number] => 20140315890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'IVABRADINE HYDROCHLORIDE FORM IV' [patent_app_type] => utility [patent_app_number] => 14/356240 [patent_app_country] => US [patent_app_date] => 2012-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4978 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 35 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14356240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10975403 [patent_doc_number] => 20140378438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/346332 [patent_app_country] => US [patent_app_date] => 2012-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17533 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14346332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10975416 [patent_doc_number] => 20140378451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'Cannabinoid-2-Receptor Agonists' [patent_app_type] => utility [patent_app_number] => 14/345790 [patent_app_country] => US [patent_app_date] => 2012-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29601 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14345790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10142193 [patent_doc_number] => 09174993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-03 [patent_title] => 'N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals' [patent_app_type] => utility [patent_app_number] => 14/345488 [patent_app_country] => US [patent_app_date] => 2012-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42845 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14345488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8607183 [patent_doc_number] => 20130012495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-10 [patent_title] => '5HT2C RECEPTOR MODULATORS' [patent_app_type] => utility [patent_app_number] => 13/617072 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 27276 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13617072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9127200 [patent_doc_number] => 08575149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-11-05 [patent_title] => '5HT2C receptor modulators' [patent_app_type] => utility [patent_app_number] => 13/620204 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 27807 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13620204 [rel_patent_id] =>[rel_patent_doc_number] =>)